Nuvation Bio (NUVB) announced updated positive long-term follow-up results from its Phase 2 J201 study of safusidenib in chemotherapy- and radiotherapy-naïve patients with grade 2 IDH1-mutant glioma. The company characterized the follow-up data as positive, supporting ongoing clinical confidence in the program, though no specific effect sizes were provided in the news brief.
Nuvation Bio (NUVB) announced updated positive long-term follow-up results from its Phase 2 J201 study of safusidenib in chemotherapy- and radiotherapy-naïve patients with grade 2 IDH1-mutant glioma. The company characterized the follow-up data as positive, supporting ongoing clinical confidence in the program, though no specific effect sizes were provided in the news brief.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
